Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 Ballot 3 World

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes

Page standards status: Informative

Raw json | Download

{
  "resourceType" : "Evidence",
  "id" : "557356",
  "meta" : {
    "versionId" : "2",
    "lastUpdated" : "2026-08-06T17:15:59.259Z",
    "profile" : [
      🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/intervention-only-evidence"
    ]
  },
  "language" : "en",
  "text" : {
    "status" : "extensions",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Evidence 557356</b></p><a name=\"557356\"> </a><a name=\"hc557356\"> </a><div style=\"display: inline-block; background-color: #fbffeb; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 2; Last updated: 2026-08-06 17:15:59+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-intervention-only-evidence.html\">InterventionOnlyEvidence</a></p></div><p><b>ArtifactPublicationStatus</b>: <span title=\"Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-status-type active}\">Active</span></p><p><b>url</b>: <a href=\"Evidence-557356.html\">Evidence MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes</a></p><p><b>identifier</b>: FEvIR Object Identifier/557356, outcomeId/313960, picoId/85798, sectionId/73215, <a href=\"http://terminology.hl7.org/7.5.0/NamingSystem-uri.html\" title=\"As defined by RFC 3986 (http://www.ietf.org/rfc/rfc3986.txt)(with many schemes defined in many RFCs). For OIDs and UUIDs, use the URN form (urn:oid:(note: lowercase) and urn:uuid:). See http://www.ietf.org/rfc/rfc3001.txt and http://www.ietf.org/rfc/rfc4122.txt \r\n\r\nThis oid is used as an identifier II.root to indicate the the extension is an absolute URI (technically, an IRI). Typically, this is used for OIDs and GUIDs. Note that when this OID is used with OIDs and GUIDs, the II.extension should start with urn:oid or urn:uuid: \r\n\r\nNote that this OID is created to aid with interconversion between CDA and FHIR - FHIR uses urn:ietf:rfc:3986 as equivalent to this OID. URIs as identifiers appear more commonly in FHIR.\r\n\r\nThis OID may also be used in CD.codeSystem.\">Uniform Resource Identifier (URI)</a>/urn:oid:2.16.840.1.113883.4.642.40.44.22.177</p><p><b>version</b>: 1.0.0-ballot3</p><p><b>name</b>: End_stage_kidney_disease_Intervention_Evidence_from_MAGICapp_313960</p><p><b>title</b>: MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes</p><p><b>citeAs</b>: </p><div><p>MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557356. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557356. Computable resource at: https://fevir.net/resources/Evidence/557356#json.</p>\n</div><p><b>status</b>: Active</p><p><b>date</b>: 2026-11-05 14:34:28+0000</p><p><b>author</b>: Computable Publishing®: MAGIC-to-FEvIR Converter: </p><p><b>publisher</b>: HL7 International / Clinical Decision Support</p><p><b>contact</b>: HL7 International / Clinical Decision Support: <a href=\"http://www.hl7.org/Special/committees/dss\">http://www.hl7.org/Special/committees/dss</a></p><h3>UseContexts</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Code</b></td><td><b>Value[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><a href=\"CodeSystem-179423.html#179423-evidence-communication\">Evidence Based Medicine on FHIR Implementation Guide Code System: evidence-communication</a> (Evidence Communication)</td><td><span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 InterventionOnlyEvidence}\">InterventionOnlyEvidence</span></td></tr></table><p><b>copyright</b>: </p><div><p>Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).</p>\n</div><h3>RelatesTos</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Target[x]</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://terminology.hl7.org/CodeSystem/artifact-relationship-type part-of}\">Part Of</span></td><td>MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)</td></tr></table><p><b>description</b>: </p><div><p>This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.</p>\n</div><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Adults with type 2 diabetes -- SGLT2 inhibitors</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: <a href=\"Group-557342.html\">SGLT2 inhibitors Group in Adults with type 2 diabetes</a></p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>End-stage kidney disease</p>\n</div><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"EvidenceVariable-236965.html\">End-stage kidney disease</a></p></blockquote><h3>Statistics</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Description</b></td><td><b>StatisticType</b></td><td><b>Quantity</b></td></tr><tr><td style=\"display: none\">*</td><td><div><p>Risk 10.9%</p>\n</div></td><td><span title=\"Codes:{https://fevir.net/sevco STATO:0000607}\">proportion</span></td><td>0.109</td></tr></table></div>"
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status",
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type",
            "code" : "active",
            "display" : "Active"
          }
        ]
      }
    }
  ],
  "url" : "https://fevir.net/resources/Evidence/557356",
  "identifier" : [
    {
      "type" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code" : "ACSN",
            "display" : "Accession ID"
          }
        ],
        "text" : "FEvIR Object Identifier"
      },
      "system" : "https://fevir.net/FOI",
      "value" : "557356",
      "assigner" : {
        "display" : "Computable Publishing LLC"
      }
    },
    {
      "type" : {
        "text" : "outcomeId"
      },
      "system" : "https://app.magicapp.org/#/guidelines",
      "value" : "313960"
    },
    {
      "type" : {
        "text" : "picoId"
      },
      "system" : "https://app.magicapp.org/#/guidelines",
      "value" : "85798"
    },
    {
      "type" : {
        "text" : "sectionId"
      },
      "system" : "https://app.magicapp.org/#/guidelines",
      "value" : "73215"
    },
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113883.4.642.40.44.22.177"
    }
  ],
  "version" : "1.0.0-ballot3",
  "name" : "End_stage_kidney_disease_Intervention_Evidence_from_MAGICapp_313960",
  "title" : "MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes",
  "citeAs" : "MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing®: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 557356. Revised 2026-08-06. Available at: https://fevir.net/resources/Evidence/557356. Computable resource at: https://fevir.net/resources/Evidence/557356#json.",
  "status" : "active",
  "date" : "2026-11-05T14:34:28+00:00",
  "author" : [
    {
      "name" : "Computable Publishing®: MAGIC-to-FEvIR Converter"
    }
  ],
  "publisher" : "HL7 International / Clinical Decision Support",
  "contact" : [
    {
      "name" : "HL7 International / Clinical Decision Support",
      "telecom" : [
        {
          "system" : "url",
          "value" : "http://www.hl7.org/Special/committees/dss"
        }
      ]
    }
  ],
  "useContext" : [
    {
      "code" : {
        "system" : "https://fevir.net/resources/CodeSystem/179423",
        "code" : "evidence-communication",
        "display" : "Evidence Communication"
      },
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "InterventionOnlyEvidence",
            "display" : "InterventionOnlyEvidence"
          }
        ]
      }
    }
  ],
  "copyright" : "Copyright the Authors else Computable Publishing LLC. Noncommercial use permitted with CC BY-NC-SA 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/). Commercial use permitted as agreed in Terms of Use (https://fevir.net/termsofuse).",
  "relatesTo" : [
    {
      "type" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/artifact-relationship-type",
            "code" : "part-of",
            "display" : "Part Of"
          }
        ]
      },
      "targetReference" : {
        "type" : "Composition",
        "identifier" : {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "MAGIC-5288-j1Wqrn-conversion-report",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        },
        "display" : "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"
      }
    }
  ],
  "description" : "This Evidence Resource is referenced in an example for the EBMonFHIR Implementation Guide.",
  "variableDefinition" : [
    {
      "description" : "Adults with type 2 diabetes -- SGLT2 inhibitors",
      "variableRole" : "population",
      "observed" : {
        🔗 "reference" : "Group/557342",
        "type" : "Group",
        "identifier" : {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "MAGIC-5288-j1Wqrn-intervention-group-MAGIC-5288-j1Wqrn-int-85798",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        },
        "display" : "SGLT2 inhibitors Group in Adults with type 2 diabetes"
      }
    },
    {
      "description" : "End-stage kidney disease",
      "variableRole" : "outcome",
      "observed" : {
        🔗 "reference" : "EvidenceVariable/236965",
        "type" : "EvidenceVariable",
        "identifier" : {
          "type" : {
            "text" : "FEvIR Linking Identifier"
          },
          "system" : "https://fevir.net/FLI",
          "value" : "MAGIC-5288-j1Wqrn-313960",
          "assigner" : {
            "display" : "Computable Publishing LLC"
          }
        },
        "display" : "End-stage kidney disease"
      }
    }
  ],
  "statistic" : [
    {
      "description" : "Risk 10.9%",
      "statisticType" : {
        "coding" : [
          {
            "system" : "https://fevir.net/sevco",
            "code" : "STATO:0000607",
            "display" : "proportion"
          }
        ]
      },
      "quantity" : {
        "value" : 0.109
      }
    }
  ]
}